Join Growin Stock Community!

Cns pharmaceuticals, inc.CNSP.US Overview

US StockHealthcare
(No presentation for CNSP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CNSP AI Insights

CNSP Overall Performance

CNSP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CNSP Recent Performance

-

Cns pharmaceuticals, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

CNSP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CNSP Key Information

CNSP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CNSP Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Price of CNSP

CNSP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CNSP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-22.75
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.19
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-22.75
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.19
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CNSP's latest earnings report released?

    The most recent financial report for Cns pharmaceuticals, inc. (CNSP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CNSP's short-term business performance and financial health. For the latest updates on CNSP's earnings releases, visit this page regularly.

  • How much cash does CNSP have?

    At the end of the period, Cns pharmaceuticals, inc. (CNSP) held Total Cash and Cash Equivalents of 9.86M, accounting for 0.83 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CNSP's EPS continuing to grow?

    According to the past four quarterly reports, Cns pharmaceuticals, inc. (CNSP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -5.76. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CNSP?

    Cns pharmaceuticals, inc. (CNSP)'s Free Cash Flow (FCF) for the period is -2.17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 68.03% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.